Afamelanotide (Scenesse, Clinuvel Pharmaceuticals) is a linear MC1R selective tridecapeptide, approved by the FDA on October 8, 2019, and by the EMA on December 22, 2014, exclusively for the treatment of erythropoietic protoporphyria (EPP) in adults
Cardiovasc Toxicol 19(6):4939
First we assessed proteolytically active proteasome subunits MECL1 , LMP2 and LMP7 required for assembly of the 20 S proteasome, protein degradation and amino acid recycling 25 , finding IGF-induced MECL1 downregulation in DU145 cells only and LMP2 downregulation in both DU145 and 22RV1 (Supplementary Figure S2A)
Cell Mol Life Sci 57 : 15351541
10 session package face & neck $4,990 Individual sessions $790- $1090 10 session package face, neck & arms/torso $8,790 Individual sessions $1190 Here is the fine print